Quantcast

Latest Sunitinib Stories

2008-07-24 12:01:21

Introgen Therapeutics has reported additional efficacy data from the company's recent regulatory filings seeking approval of Advexin in the US and Europe. These findings resulted from supportive statistical analyses based on data from the pivotal Phase III clinical trial of Advexin in patients with recurrent, refractory head and neck cancer. These analyses evaluated the length of survival of patients in the biomarker population receiving Advexin as compared to patients in the biomarker...

2008-06-17 09:01:12

BELLEVUE, WA, June 17 /PRNewswire-FirstCall/ -- Oncothyreon Inc. (TSX:ONY) today announced enrollment of the first patient in a Phase 1 trial of PX-866 in patients with advanced solid tumors. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), an important cell survival signaling pathway. "PX-866 is a potent inhibitor of PI-3K, a component of a critical pathway that is activated in many types of cancer, leading to tumor growth and...

2008-06-17 09:01:12

By Barry Nelson A PROFESSOR who successfully "declared war" on cancer in France has urged the British Government to give more priority to the disease. Professor David Khayat, who founded the French National Cancer Institute, spoke to The Northern Echo about France's cancer drugs revolution, as part of the paper's End NHS Injustice campaign. Last night, North-East cancer patients who have been denied access to potentially life-extending new drugs available in France urged the Government...

2008-05-31 09:00:07

COLLEGEVILLE, Pa., May 31 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , today announced results of a three-arm phase 3 clinical trial that show patients with relapsed and/or refractory mantle cell lymphoma (MCL), a form of non-Hodgkin's lymphoma, treated with the mTOR (mammalian target of rapamycin) inhibitor TORISEL(R) (temsirolimus) experienced a statistically significant improvement in median progression-free survival (PFS), compared with single-agent therapy...

2006-06-04 13:20:34

Please read in fourth paragraph ... "24 weeks from 12 weeks" ... instead of ... "24 months from 12 months" A corrected repetition follows: By Toni Clarke ATLANTA (Reuters) - For the first time in decades there are new treatments available for kidney cancer, and as more data emerges about their efficacy, the competition looks set to heat up. Data presented on Sunday at the annual meeting of the American Society of Clinical Oncology confirmed the potency of Sutent, a drug marketed...

2006-06-04 13:28:37

By Toni Clarke ATLANTA (Reuters) - A kidney cancer drug made by Bayer AG and Onyx Pharmaceuticals Inc. showed promise in a small lung cancer trial, according to data released on Sunday, further fueling competition with a drug from Pfizer Inc. Results presented at the annual meeting of the American Society of Clinical Oncology showed that in a trial of 52 patients with advanced non-small cell lung cancer who had failed previous treatment, 59 percent of patients who took the drug,...

2006-06-04 11:31:45

By Toni Clarke ATLANTA (Reuters) - For the first time in decades there are new treatments available for kidney cancer, and as more data emerges about their efficacy, the competition looks set to heat up. Data presented on Sunday at the annual meeting of the American Society of Clinical Oncology confirmed the potency of Sutent, a drug marketed by Pfizer Inc. that was approved by U.S. regulators in January. For the first time, too, data was released from a late-stage, or Phase III,...

2006-06-04 06:06:43

By Toni Clarke ATLANTA (Reuters) - Wyeth said on Sunday that interim results of a late-stage trial of its experimental kidney cancer drug significantly increased survival in patients compared to standard therapy. Patients with advanced kidney cancer who took the drug, temsirolimus, had a median survival time of 10.9 months, compared to a survival time of 7.3 months for patients who took the standard therapy. Data from the late-stage, or Phase III, trial were presented at the annual...

2006-06-04 06:01:57

By Ransdell Pierson NEW YORK (Reuters) - Pfizer Inc.'s kidney cancer drug Sutent will soon become the favored first-line treatment for advanced forms of the disease, based on its ability to prolong survival in a late-stage trial described on Sunday, researchers said. Sutent was approved in January as a second-line treatment for advanced kidney cancer, meaning for patients whose cancer spread despite their earlier use of the standard drugs interferon and interleukin-2, which are...

2006-06-03 15:11:46

By Toni Clarke ATLANTA (Reuters) - Using combinations of "smart bomb" cancer drugs that target specific proteins and avoid the indiscriminate cell destruction of chemotherapy may be the wave of the future for cancer patients, experts say. Early studies show that combining targeted treatments such as Genentech Inc.'s breast cancer drug Herceptin with GlaxoSmithKline Plc's experimental treatment Tykerb, may be helpful in patients who do not respond to Herceptin alone, said Dr. Jose...


Word of the Day
pungle
  • To take pains; labor assiduously with little progress.
This word comes from the Spanish 'pongale,' put it.
Related